Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Metadata
Title
History of treatment and long-term outcome of childhood acute lymphoblastic leukemia in Slovenia
Authors
S. Avcin
T. Prelog
M. Kavcic
L. Kitanovski
J. Anzic
M. Benedik Dolnicar
V. Rajic
L. Zadravec Zaletel
M. Debeljak
J. Jazbec
Publication date
01-09-2011
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 3/2011
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-011-0278-z

Other articles of this Issue 3/2011

memo - Magazine of European Medical Oncology 3/2011 Go to the issue

Editorial

Long-term results of national treatment trials in childhood acute lymphoblastic leukaemia in several Middle/East European countries

Original report

The use of mammographic tumour feature significantly improves outcome prediction of breast cancers smaller than 15 mm: a reproducibility study from two comprehensive breast centres

Short review

Results of acute lymphoblastic leukemia treatment in children in the Slovak Republic

Short review

History of treatment and long-term outcome in children with acute lymphoblastic leukaemia in Serbia

Short review

Long-term results in children with standard risk acute lymphoblastic leukaemia treated with 5.0 g/m2 versus 3.0 g/m2 methotrexate i.v. according to the modified ALL-BFM 90 protocol. The report of Polish paediatric Leukemia/lymphoma study group

Short review

Molecular genetic tests in the prediction of the prognosis of breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits